Bevacizumab, Idarubicin, and Cytarabine in Treating Patients With Blast Phase Chronic Myelogenous Leukemia

NCT00023920 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

60

Enrollment

NIH

Sponsor class

Stopped Administratively complete.

Conditions

Blastic Phase Chronic Myelogenous Leukemia
Chronic Myelogenous Leukemia, BCR-ABL1 Positive

Interventions

BIOLOGICAL: bevacizumab
DRUG: idarubicin
DRUG: cytarabine

Sponsor

National Cancer Institute (NCI)